The filings cover Amondys 45 and Vyondys 53, therapies currently operating under accelerated status. This regulatory step offers a reprieve for investors who feared the company’s path might narrow following a Phase 3 trial that failed to reach statistical significance. Analysts at Mizuho characterized the acceptance as a positive signal, suggesting that the risk of market withdrawal remains minimal.
In section Market Quotes
Sarepta Therapeutics Rallies as FDA Reviews Traditional Approval Path
Sarepta Therapeutics shares climbed 5.4% to $17.93 in Tuesday trading, shaking off a 17% year-to-date decline after the FDA accepted supplemental applications for two Duchenne muscular dystrophy treatments. The agency set a target action date of February 28, 2027, for the drugmaker’s bid to secure traditional, non-accelerated approval.
Experts point to the ultra-rare nature of the patient populations affected by exon 45 and exon 53 mutations, combined with real-world clinical evidence, as key factors supporting the treatments' longevity. Duchenne muscular dystrophy causes progressive muscle degeneration and weakness, leaving few alternatives for those afflicted by the genetic disorder.
Comments (0)
No comments yet. Be the first!